Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN— A Randomized, Phase III Study
Journal of clinical oncology, 2014-07, Vol.32 (19), p.2039-2049 [Peer Reviewed Journal]2015 INIST-CNRS ;2014 by American Society of Clinical Oncology. ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2013.53.6136 ;PMID: 24868024
Full text available